
    
      This is a phase 1, open label, single-dose, crossover study to investigate the
      pharmacokinetics of YHP1604 in comparison to the co-administration of telmisartan/amlodipine
      and rosuvastatin in healthy male volunteers.

      In ARM1, 30 subjects will be assigned and the subjects will be administered
      "telmisartan/amlodipine and rosuvastatin" at Day1 and "YHP1604" at Day22.

      In ARM2, 30 subjects will be assigned and the subjects will be administered "YHP1604" at Day1
      and "telmisartan/amlodipine and rosuvastatin" at Day22.
    
  